Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 10 - Share Capital (Details Textual)

Note 10 - Share Capital (Details Textual)							3 Months Ended		5 Months Ended	9 Months Ended		11 Months Ended	12 Months Ended	18 Months Ended
Note 10 - Share Capital (Details Textual)	Jan. 13, 2025 Days $ / shares	Sep. 11, 2024 USD ($) $ / shares shares	Jun. 03, 2024 USD ($) $ / shares shares	Jan. 31, 2024 USD ($) $ / shares shares	Sep. 06, 2023 USD ($) shares	May 25, 2023 USD ($) shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	May 30, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares	Apr. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	May 30, 2024 USD ($) $ / shares	Sep. 05, 2024	Jul. 16, 2024 $ / shares	Apr. 01, 2024	Feb. 29, 2024	Aug. 10, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 09, 2022 USD ($)	Nov. 04, 2021 shares
Nasdaq Listing Rule, minimum requirement for stockholders' equity							$ 2,500,000			$ 2,500,000			$ 2,500,000
Negative shareholder's equity							$ (9,134,000)	$ 7,776,000		$ (9,134,000)	$ 7,776,000		$ (2,901,000)							$ 37,741,000
Common shares issued (in shares) \| shares		1,395,000
Pre-Funded warrants exercised \| shares		1,395,000
Cash proceeds		$ 1,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 0.001
Percentage of shares outstanding															20.00%
Financing costs including underwriting costs, professional fees and recognition of deferred financing costs			$ 408,000,000	$ 1,400,000
Underwriting costs (as percent)			7.00%
Warrants to purchase common shares, exchange price \| $ / shares		$ 0.001
Common Stock, Shares Outstanding \| shares							19,521,183			19,521,183			7,942,363
Cash proceeds from issuing shares											1,185,000
Common Shares [Member]
Negative shareholder's equity							$ 452,302,000	443,938,000		$ 452,302,000	443,938,000		$ 444,806,000							$ 437,520,000
Cash proceeds from issuing shares											1,185,000
Forecast [Member] \| Common Shares [Member]
Common stock, par value \| $ / shares	$ 1
Description of subsequent event	The Company has been given 180 calendar days, or until January 13, 2025, to regain compliance with the Minimum Bid Price Requirement. If at any time before January 13, 2025, the bid price of the Company’s Common Shares closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance with the Minimum Bid Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by January 13, 2025, the Company may, at Nasdaq's discretion, be afforded a second 180 calendar day period to regain compliance, but if Nasdaq does not grant such extension, the Company's common shares could be delisted from Nasdaq
Consecutive business days \| Days	10
Warrant [Member] \| Common Shares [Member]
Common warrants offering price \| $ / shares				$ 1.71
Hanmi Pharmaceuticals Co Ltd [Member]
Proceeds from issuance of common stock					$ 3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 1.71
Underwriting costs (as percent)				7.00%
Professional fees				$ 400,000
Warrants to purchase common shares, exchange price \| $ / shares				$ 1.71
Common Stock, Shares Outstanding \| shares							2,989,415			2,989,415
Number of common shares held \| shares																						215,703
Hanmi Pharmaceuticals Co Ltd [Member] \| Common Shares [Member]
Number of shares sold \| shares					668,449
Maximum [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Investment for ownership interest																			$ 7,000,000
Percentage of investment																			19.99%
Minimum [Member]
Common stock, par value \| $ / shares																$ 1
Percentage of common shares outstanding.																		19.99%
Private placement issuance percentage																		20.00%
2023 Committed Equity Facility [Member]
Stock issuance program authorized shares \| shares						25,156
Common shares issued (in shares) \| shares													720,494
Proceeds from issuance of common stock													$ 2,100,000
Stock Issuance Program, Authorized Amount						$ 25,000,000
Percentage of common shares outstanding.						19.99%
Shares issued, price per share (in dollars per share) \| $ / shares													$ 2.91
2023 Committed Equity Facility [Member] \| Keystone [Member]
Common shares issued (in shares) \| shares										510,101		1,230,595
Proceeds from issuance of common stock										$ 694		$ 2,800,000
Percentage of common shares outstanding.																	19.99%
Shares issued, price per share (in dollars per share) \| $ / shares							$ 1.36			$ 1.36		$ 2.27
Financing costs including underwriting costs, professional fees and recognition of deferred financing costs										$ 82,000		$ 168,000
2023 Committed Equity Facility [Member] \| Initial Commitment Shares [Member]
Common shares issued (in shares) \| shares						7,547
Stock Issuance, Percent of Cash Commission to Broker						30.00%
2023 Committed Equity Facility [Member] \| First Back-End Commitment Shares [Member]
Common shares issued (in shares) \| shares						7,547
Stock Issuance, Percent of Cash Commission to Broker						30.00%
2023 Committed Equity Facility [Member] \| Commitment Shares [Member]
Common shares issued (in shares) \| shares										10,062			15,094
2023 Committed Equity Facility [Member] \| Commitment Shares [Member] \| Keystone [Member]
Common shares issued (in shares) \| shares										10,062		25,156
The 2022 ATM Offering [Member]
Common shares issued (in shares) \| shares									81,591
Proceeds from issuance of common stock							$ 0	$ 694,000	$ 97,000	$ 97,000	1,837,000			$ 2,000,000
Stock Issuance Program, Authorized Amount																					$ 50,000,000
Shares issued, price per share (in dollars per share) \| $ / shares									$ 1.22					$ 1.22
Proceeds from Issuance of Common Stock, Gross									$ 100,000,000					$ 2,100,000
Stock Issuance, Percent of Cash Commission to Broker							3.00%			3.00%
Cash proceeds from issuing shares										$ (21,000)	$ 1,828,000
The 2022 ATM Offering [Member] \| Common Shares [Member]
Common shares issued (in shares) \| shares										82,000	337,000
Cash proceeds from issuing shares										$ 97,000	$ 1,828,000
June 2024 Registered Direct Offering [Member]
Common shares issued (in shares) \| shares			1,800,000
Shares issued, price per share (in dollars per share) \| $ / shares							$ 1.15			$ 1.15
Proceeds from Issuance of Common Stock, Gross			$ 4,430,000
June 2024 Registered Direct Offering [Member] \| Pre-Funded Warrants [Member]
Warrants issued \| shares			2,055,000
Warrants purchase price per share \| $ / shares			$ 1.149
Private Placement [Member]
Warrants to purchase common shares, number of warrants \| shares			192,750
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 1.44
Warrants, Remaining contractual life			5 years
Warrants to purchase common shares, exchange price \| $ / shares			$ 1.44
Private Placement [Member] \| Series A Warrants [Member]
Warrants, Remaining contractual life			5 years
Private Placement [Member] \| Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 1.15
Warrants, Remaining contractual life			18 months
Warrants to purchase common shares, exchange price \| $ / shares			$ 1.15
Private Placement [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Common shares issued (in shares) \| shares				2,105,263
Proceeds from issuance of common stock				$ 4,000,000
Shares issued, price per share (in dollars per share) \| $ / shares				$ 1.9
Private Placement [Member] \| Maximum [Member] \| Series A Warrants [Member]
Warrants to purchase common shares, number of warrants \| shares			3,855,000
Private Placement [Member] \| Maximum [Member] \| Series B Warrants [Member]
Warrants to purchase common shares, number of warrants \| shares			3,855,000
Public Offering [Member]
Common shares issued (in shares) \| shares				5,649,122
Public Offering [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Proceeds from issuance of common stock				$ 9,700,000
Premium Share Price Percent				11.00%
Over-Allotment Option [Member]
Common shares issued upon exercise of stock options				$ 736,842